Published in Hepatitis Weekly, September 4th, 2006
Study 1: Recent research from Spain has chronicled the effect of calcineurin inhibitors on survival and histologic disease severity in hepatitis C virus (HCV)-infected liver transplant recipients.
"The severity of recurrent HCV is likely related to several factors. Controversial results have been reported regarding the effect of specific calcineurin-inhibitors. The aim of this research was to determine whether there are differences on posttransplantation outcome in HCV-infected patients based on initial immunosuppression," wrote M. Berenguer and colleagues,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2006-09-04)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.